Johnson & Johnson Reports New Long-Term Data from P-III (MARIPOSA) Trial of Rybrevant Plus Lazcluze for Advanced NSCLC
Shots:
- J&J has reported long term follow-up data from the P-III (MARIPOSA) trial assessing Rybrevant + Lazcluze vs osimertinib or Lazcluze alone as a 1L treatment of locally advanced or metastatic NSCLC patients (n=1,074) with EGFR ex19del or L858R substitution mutations. 1EP was PFS
- At a median follow-up of 31.1mos., 61% vs 53% patients were alive with mOS not estimable vs 37.3mos. The 2EP of OS will continue to be monitored with longer term follow-up
- Furthermore, a trend favoring improved CNS disease control was observed at 3yrs. The intracranial PFS was 38% vs 18% with 40% vs 29% remaining on the treatment and 45% vs 32% not starting subsequent therapy; PFS after first subsequent therapy was 57% vs 49%
Ref: Johnson & Johnson | Image: Johnson & Johnson
Related Post:- Johnson & Johnson Reports the US FDA’s Approval of Rybrevant + Lazcluze as a 1L Treatment of NSCLC with EGFR Mutations
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
